Literature DB >> 16545476

Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes.

Martin Savard1, Jean Gosselin.   

Abstract

Epstein-Barr virus (EBV) is an oncogenic human herpesvirus that persistently infects approximately 90% of the world's population. Such a remarkably sustained of viral infectivity relies on EBV's ability to evade the host immune defenses. A crucial part of this anti-EBV response is mediated by cytotoxic CD8+ T lymphocytes, which maintain a life-long control over proliferating latently-infected B cells in order to prevent these from giving rise to lymphomatous diseases. On the other hand, little has been done to assess the role of phagocytes-mediated innate immunity in the pathogenesis of EBV infection. In the course of primary EBV infection, episodes of neutropenia and monocytopenia can be observed during the acute phase of infection. According to the role of those cells in the non specific and specific immunity, such a decrease in circulating phagocytes may then temporarily affect the immune defense and potentially influence the outcome of EBV infection. Recent studies have demonstrated that EBV infects both neutrophils and monocytes and modulates several of their biological functions. This review covers the current state of our knowledge relative to the role of neutrophils and monocytes in EBV pathogenesis and describes the nature of countermeasures deployed by EBV against these cells.

Entities:  

Mesh:

Year:  2006        PMID: 16545476     DOI: 10.1016/j.virusres.2006.02.008

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  17 in total

1.  Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9.

Authors:  Ying Zheng; Zailong Qin; Qiurong Ye; Pan Chen; Zhen Wang; Qun Yan; Zhaohui Luo; Xiaoping Liu; Yanhong Zhou; Wei Xiong; Jian Ma; Guiyuan Li
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

Review 2.  Evaluation and management of patients with isolated neutropenia.

Authors:  Peter E Newburger; David C Dale
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

Review 3.  Autoimmune and other acquired neutropenias.

Authors:  Peter E Newburger
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Epstein-Barr virus associated peri-implantitis: a split-mouth study.

Authors:  Fernando Verdugo; Ana Castillo; Francisca Castillo; Agurne Uribarri
Journal:  Clin Oral Investig       Date:  2014-05-07       Impact factor: 3.573

5.  Epstein-Barr virus interferes with the amplification of IFNalpha secretion by activating suppressor of cytokine signaling 3 in primary human monocytes.

Authors:  François Michaud; François Coulombe; Eric Gaudreault; Carine Paquet-Bouchard; Marek Rola-Pleszczynski; Jean Gosselin
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240

6.  HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection.

Authors:  Karen A McAulay; Craig D Higgins; Karen F Macsween; Annette Lake; Ruth F Jarrett; Faye L Robertson; Hilary Williams; Dorothy H Crawford
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 7.  Fresh Insights into Disease Etiology and the Role of Microbial Pathogens.

Authors:  Antonella Farina; G Alessandra Farina
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 8.  Neutrophil in viral infections, friend or foe?

Authors:  Brandon Drescher; Fengwei Bai
Journal:  Virus Res       Date:  2012-11-21       Impact factor: 3.303

9.  Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2.

Authors:  Eric Gaudreault; Stéphanie Fiola; Martin Olivier; Jean Gosselin
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 10.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.